Fibroblast growth factor 21 (FGF21) in human cerebrospinal fluid: Relationship with plasma FGF21 and body adiposity

Diabetes

Volumn 60, Issue 11, 2011, Pages 2758-2762

  Tan, Bee K ^a,b   Hallschmid, Manfred ^c   Adya, Raghu ^a   Kern, Werner ^c   Lehnert, Hendrik ^a,c   Randeva, Harpal S ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; FIBROBLAST GROWTH FACTOR 21; INSULIN;

ADULT; AGED; ARTICLE; BODY FAT; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; METABOLIC PARAMETERS; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL;

ADIPONECTIN; ADIPOSE TISSUE; ADIPOSITY; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; BODY MASS INDEX; BODY WEIGHT; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; OBESITY; OVERWEIGHT;

EID: 80755168936     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db11-0672     Document Type: Article

References (25)

1. Ornitz DM, Itoh N. Fibroblast growth factors. Genome Biol 2001;2:REVIEWS3005
2. Gospodarowicz D. Localisation of a fibroblast growth factor and its effect alone and with hydrocortisone on 3T3 cell growth. Nature 1974;249:123-127
3. Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 2009;8:235-253
4. Inagaki T, Choi M, Moschetta A, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005;2:217-225
5. ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 2000;26:345-348
6. Kharitonenkov A, Shiyanova TL, Koester A, et al. FGF-21 as a novel metabolic regulator. J Clin Invest 2005;115:1627-1635 (Pubitemid 40814671)
7. Zhang X, Yeung DC, Karpisek M, et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008;57:1246-1253
8. Gälman C, Lundåsen T, Kharitonenkov A, et al. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Cell Metab 2008;8:169-174
9. Li L, Yang G, Ning H, Yang M, Liu H, Chen W. Plasma FGF-21 levels in type 2 diabetic patients with ketosis. Diabetes Res Clin Pract 2008;82:209-213
10. Li K, Li L, Yang M, Zong H, Liu H, Yang G. Effects of rosiglitazone on fasting plasma fibroblast growth factor-21 levels in patients with type 2 diabetes mellitus. Eur J Endocrinol 2009;161:391-395
11. Lin Z, Zhou Z, Liu Y, et al. Circulating FGF21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in Chinese. PLoS ONE 2011;6:e18398
12. Coskun T, Bina HA, Schneider MA, et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 2008;149:6018-6027
13. Enriori PJ, Evans AE, Sinnayah P, et al. Diet-induced obesity causes severe but reversible leptin resistance in arcuate melanocortin neurons. Cell Metab 2007;5:181-194
14. Hsuchou H, Pan W, Kastin AJ. The fasting polypeptide FGF21 can enter brain from blood. Peptides 2007;28:2382-2386 (Pubitemid 350116319)
15. Sarruf DA, Thaler JP, Morton GJ, et al. Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats. Diabetes 2010;59:1817-1824
16. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419 (Pubitemid 15018832)
17. Mraz M, Bartlova M, Lacinova Z, et al. Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin Endocrinol (Oxf) 2009;71:369-375
18. Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW. Central nervous system control of food intake and body weight. Nature 2006;443:289-295 (Pubitemid 44435142)
19. Fisher FM, Chui PC, Antonellis PJ, et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 2010;59:2781-2789
20. Dostálová I, Kaválková P, Haluzíková D, et al. Plasma concentrations of fibroblast growth factors 19 and 21 in patients with anorexia nervosa. J Clin Endocrinol Metab 2008;93:3627-3632
21. Matuszek B, Lenart-Lipińska M, Duma D, Solski J, Nowakowski A. Evaluation of concentrations of FGF-21 - a new adipocytokine in type 2 diabetes. Endokrynol Pol 2010;61:50-54
22. Kos K, Harte AL, da Silva NF, et al. Adiponectin and resistin in human cerebrospinal fluid and expression of adiponectin receptors in the human hypothalamus. J Clin Endocrinol Metab 2007;92:1129-1136 (Pubitemid 46465692)
23. Dridi S, Taouis M. Adiponectin and energy homeostasis: consensus and controversy. J Nutr Biochem 2009;20:831-839
24. Yamashita T, Yoshioka M, Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun 2000;277:494-498
25. Nam SY, Kratzsch J, Kim KW, Kim KR, Lim SK, Marcus C. Cerebrospinal fluid and plasma concentrations of leptin, NPY, and alpha-MSH in obese women and their relationship to negative energy balance. J Clin Endocrinol Metab 2001;86:4849-4853 (Pubitemid 33020531)